Member access

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesHot NewsMost Read NewsRecomm.Business LeadersVideosCalendar 

Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment

07/16/2014 | 08:45pm US/Eastern

By a News Reporter-Staff News Editor at Cancer Weekly -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, announced it has entered into an agreement with Merck KGaA, Darmstadt, Germany, which operates as EMD Serono in the United States and Canada, to collaborate with Merck KGaA's biopharmaceutical division on the development and commercialization of a companion diagnostic (CDx) for an undisclosed target using Ventana's proprietary diagnostic assays. In alignment with Merck KGaA's strategic approach in personalized medicine, the aim is to develop a patient stratifying diagnostic test that can be used in multiple cancer indications. Merck KGaA, which is actively investing in innovation in the CDx field through a number of partnerships, will leverage Ventana's global leadership position in cancer diagnostics and vast expertise in CDx to achieve new levels of diagnostic clarity for the investigated target. As part of the agreement, Ventana will develop and validate the CDx and ensure its readiness, availability, and adherence to FDA and other health authority standards for future clinical trials (see also Ventana Medical Systems, Inc.).

"Tailoring therapies based on a patient's specific genes, proteins or tissue environment is a key expansion area for oncology. We are very pleased to partner with Merck in Darmstadt, Germany to co-develop a CDx that will play a vital role in improving the quality of care for cancer patients," said Doug Ward, Vice President, Companion Diagnostics, Ventana Medical Systems, Inc. "Ventana is committed to continuing to provide the industry's gold standard in biomarker detection using our proprietary assays as the basis for novel companion diagnostic tests."

This pharma partnership is one of several currently underway where the Ventana Companion Diagnostics team is delivering patient stratifying diagnostic tests that help identify those patients who are most likely to benefit from specific treatments. In addition to the biopharmaceutical division of Merck KGaA, Ventana has announced partnerships with Bayer, Pfizer, Boehringer Ingelheim, Takeda's Millennium unit, Genmab, Incyte, MedImmune and more. Since 2002, the company has worked with more than 45 biopharmaceutical partners and is currently engaged in more than 180 collaborative projects to develop and commercialize companion diagnostics globally.

Companion diagnostics (CDx) are tests designed to confirm the presence of a specific biomarker to assist physicians in selecting effective therapies for their patients, based on the individual characteristics of each person. Incorporating a companion diagnostic strategy into a drug development program may expedite the drug approval process and help generate more effective treatments with improved safety profiles for patients.

Keywords for this news article include: Cancer, Genetics, Oncology, Ventana Medical Systems Inc.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC

(c) 2014 NewsRx LLC

React to this article
Latest news
Date Title
1m ago GOOGLE 'C' : joins global wave of mourning to pay tribute to late Hughes
4m ago RIKEN : Kyodo Top12 News (16:10)
22m ago WEST TEXAS RESOURCES : Oncor Announces Electric System Enhancements
25m ago WAL MART STORES : Walmart protesters demand better wages
26m ago GOOGLE 'C' : Idea Grove Publishes '16 SEO Myths You Should Leave Behind in 2014' eBook
26m ago FERROVIAL : Sheffield City Road Traffic Electricians Strike in Pay Dispute
26m ago CT MAINE 6P : CMP Storm Recovery Nears 100,000 Mark
28m ago CT MAINE 6P : CMP Storm Recovery Passes 90 percent Mark, Restoring Power to Nearly 95,000 Homes and Businesses Since Thanksgiving Day
28m ago CT MAINE 6P : CMP Continues Push to Recover from Winter Storm
30m ago AFCON : Keshi should take blame, says Oliseh
Latest news
Advertisement
Hot News 
DIXONS CARPHONE : Currys PC World stands poised for one order every second on Black Friday
PROXAMA : In Final Stages For Proposed Aconite Acquisition (ALLISS)
ZHONGDE WASTE TECHNOLOGY : Strong year-on-year improvement of financial results in the first nine months 2014 (DGAP News)
MJ GLEESON : Expects Results To Beat Expectations On Strong Homes Unit
AUGEAN : Chairman Buys 55,000 Shares (DIRECTOR DEALINGS)
Most Read News
1d agoDJSTOCKTON : Bankruptcy Exit Should Move Ahead
1d ago NGEX RESOURCES : Updated Share Capital and Voting Rights for NGEx
1d ago U.S. Black Friday shopping marked by thinner crowds, protests
1d ago DEUTSCHE LUFTHANSA : German pilots union says fresh strikes imminent at Lufthansa
1d ago KINDER MORGAN : Pipeline survey crews wrap early in disputed zone at centre of B.C. protests, arrests
Most recommended articles
1d ago As energy shares tumble, opportunity lurks
1d ago Dollar Ready to Take Advantage of Market Unease But Rates at Risk
1d agoDJSTOCKTON : Bankruptcy Exit Should Move Ahead
1d agoDJWal-Mart and Target Take Fight to Amazon for Holiday Sales
1d ago AUD Exposed To Further Declines As Yield Advantage Erodes
Dynamic quotes  
ON
| OFF